As a result, by inhibiting the PD-1–PD-L1 axis, a profound anti-tumor effect could be expected by restoring the metabolic fitness of T cells while downregulating aerobic glycolysis in tumor cells, thereby also increasing the availability of glucose to the T cells [216]. Here, CD274 is linked to neoplasm.